dr. kahl on frontline therapy selection in cll
Published 5 years ago • 117 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
1:53
dr. kahl on frontline btk inhibitor selection in cll
-
2:03
dr. kahl on considerations for treatment strategies in cll
-
1:32
dr. kahl on findings from the l-mind study with tafasitamab in dlbcl
-
25:12
enhancing clinical outcomes in cll through selection of optimal frontline therapy
-
1:43
dr. kahl on ibrutinib in cll
-
0:15
copy of dr. kahl on patient preference in treatment selection for cll
-
0:54
dr. kahl on patient preference in treatment selection for cll
-
3:18
collaborate | understanding your cll diagnosis
-
1:07
dr. kahl discusses the potential of frontline ibrutinib in mcl
-
8:16
optimizing frontline therapy selection and follow-up in cll
-
1:01
dr. kahl on btk inhibitor time-definite trials in cll
-
0:57
dr. kahl discusses unmet needs in mcl
-
2:05
dr. kahl on the impact of venetoclax in chronic lymphocytic leukemia
-
1:33
dr. kahl on the utility of tafasitamab/lenalidomide in dlbcl
-
2:02
dr. kahl on promising research in chronic lymphocytic leukemia
-
4:22
progression on frontline ibrutinib in cll
-
4:20
selecting the optimal frontline therapy in cll
-
6:53
frontline therapy in cll: combination strategies and mrd
-
6:24
selecting frontline therapy for cll